Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DMU9P2
|
|||
Drug Name |
Efanesoctocog alfa
|
|||
Synonyms |
BIVV001; Altuviiio
Click to Show/Hide
|
|||
Drug Type |
Protein
|
|||
Indication | Haemophilia A [ICD-11: 3B10.0; ICD-9: 286] | Approved | [1] | |
Company |
Sanofi
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Coagulation factor VIII (F8) | Target Info | Replacement | [2] |
KEGG Pathway | Complement and coagulation cascades | |||
Panther Pathway | Blood coagulation | |||
Pathwhiz Pathway | Coagulation | |||
Reactome | Platelet degranulation | |||
Intrinsic Pathway of Fibrin Clot Formation | ||||
Common Pathway of Fibrin Clot Formation | ||||
COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
Cargo concentration in the ER | ||||
WikiPathways | Complement and Coagulation Cascades | |||
Blood Clotting Cascade | ||||
Formation of Fibrin Clot (Clotting Cascade) |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Sanofi | |||
REF 2 | Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022 Feb 22;6(4):1089-1094. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.